InMode Ltd.

DB:154 Stock Report

Market Cap: €1.5b

InMode Valuation

Is 154 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 154 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 154 (€18.03) is trading below our estimate of fair value (€33.77)

Significantly Below Fair Value: 154 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 154?

Key metric: As 154 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 154. This is calculated by dividing 154's market cap by their current earnings.
What is 154's PE Ratio?
PE Ratio10.5x
EarningsUS$153.67m
Market CapUS$1.61b

Price to Earnings Ratio vs Peers

How does 154's PE Ratio compare to its peers?

The above table shows the PE ratio for 154 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.7x
EUZ Eckert & Ziegler
24.5x5.9%€879.3m
DRW3 Drägerwerk KGaA
7.2x2.0%€798.0m
AFX Carl Zeiss Meditec
25.4x16.3%€5.2b
SBS Stratec
33.6x25.4%€336.7m
154 InMode
10.5x7.5%€1.6b

Price-To-Earnings vs Peers: 154 is good value based on its Price-To-Earnings Ratio (10.5x) compared to the peer average (22.7x).

Price to Earnings Ratio vs Industry

How does 154's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
154 10.5xIndustry Avg. 29.7xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 154 is good value based on its Price-To-Earnings Ratio (10.5x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is 154's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

154 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.5x
Fair PE Ratio21.1x

Price-To-Earnings vs Fair Ratio: 154 is good value based on its Price-To-Earnings Ratio (10.5x) compared to the estimated Fair Price-To-Earnings Ratio (21.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 154 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.03
€20.35
+12.9%
17.3%€25.76€16.22n/a6
Nov ’25€15.61
€19.69
+26.1%
17.3%€24.92€15.69n/a6
Oct ’25€14.01
€19.05
+36.0%
21.3%€26.30€14.51n/a5
Sep ’25€14.24
€19.24
+35.1%
21.3%€26.57€14.66n/a5
Aug ’25€16.61
€19.54
+17.7%
20.5%€26.73€14.75n/a5
Jul ’25€17.15
€23.78
+38.7%
19.9%€30.65€18.58n/a5
Jun ’25€17.49
€23.78
+36.0%
19.9%€30.65€18.58n/a5
May ’25€15.93
€25.72
+61.5%
14.6%€30.76€19.57n/a5
Apr ’25€19.42
€26.47
+36.3%
15.8%€31.69€19.57n/a5
Mar ’25€20.20
€26.47
+31.0%
15.8%€31.69€19.57n/a5
Feb ’25€21.68
€25.73
+18.7%
16.8%€30.32€19.30n/a5
Jan ’25€20.48
€28.36
+38.5%
27.6%€40.90€19.09n/a5
Dec ’24€22.52
€30.59
+35.8%
29.4%€40.96€20.03n/a5
Nov ’24€18.09
€38.99
+115.5%
29.8%€51.35€20.92€15.615
Oct ’24€28.98
€50.38
+73.8%
5.4%€55.47€47.29€14.015
Sep ’24€35.76
€50.38
+40.9%
5.4%€55.47€47.29€14.245
Aug ’24€38.66
€50.38
+30.3%
5.4%€55.47€47.29€16.615
Jul ’24€33.42
€43.88
+31.3%
8.8%€49.49€37.35€17.155
Jun ’24€29.92
€43.88
+46.7%
8.8%€49.49€37.35€17.495
May ’24€32.88
€44.25
+34.6%
9.6%€48.86€36.88€15.935
Apr ’24€28.60
€44.25
+54.7%
9.6%€48.86€36.88€19.425
Mar ’24€32.80
€45.82
+39.7%
6.2%€49.56€42.08€20.205
Feb ’24€32.60
€47.73
+46.4%
10.2%€56.53€41.45€21.686
Jan ’24€32.97
€47.73
+44.8%
10.2%€56.53€41.45€20.486
Dec ’23€36.35
€52.63
+44.8%
8.9%€60.73€47.57€22.525
Nov ’23€34.69
€52.63
+51.7%
8.9%€60.73€47.57€18.095

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%